OpenAI has acquired Orchestra Bio, a drug development platform, as the artificial intelligence company expands its presence in life sciences, according to ANI. The acquisition signals OpenAI’s growing interest in applying AI technologies to biotechnology and drug development. The move could support efforts to explore how advanced AI tools can contribute to scientific research and accelerate aspects of the drug discovery process. The deal marks another step in the intersection of artificial intelligence and healthcare innovation.
